Metformin and cancer mortality
The author analyses recent publications supporting the ability of metformin to decrease the risk of cancer morbidity and mortality in patients with type 2diabetes mellitus. Pre-history of the problem (including the use of biguanides for metabolic rehabilitation of oncological patients), the role of...
Saved in:
| Main Author: | |
|---|---|
| Format: | article |
| Language: | EN RU |
| Published: |
Endocrinology Research Centre
2010
|
| Subjects: | |
| Online Access: | https://doaj.org/article/05da729af1a04fbb8decb7c01a66bd6a |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The author analyses recent publications supporting the ability of metformin to decrease the risk of cancer morbidity and mortality in patients with type 2diabetes mellitus. Pre-history of the problem (including the use of biguanides for metabolic rehabilitation of oncological patients), the role of DM as a riskfactor of cancer morbidity and mortality, mechanisms and targets of metformin anticancer effects, and potential use of this agent in non-diabetic patientsare discussed. The need for the search of the markers of sensitivity and resistance to metformin to be used in oncological practice is emphasized. |
|---|